Pasithea Therapeutics Corp. — Director's Dealing 2022

Oct 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-10-21

Reporting Person: Novak Alfred J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-21	Stock Option (to acquire Common Stock)	$1.06	A	100000	Acquired	2032-10-21	Common Stock (100000)	Direct

Footnotes

F1: The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to Mr. Novak's continued service as a director, one-half vesting on the first anniversary of the grant date, and the remaining 50% vesting on the second anniversary of the grant date.